Skip to main
BVS

Bioventus (BVS) Stock Forecast & Price Target

Bioventus (BVS) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Bioventus is a medical device company with a strong fourth quarter result and robust financial guidance for the future. Their top line revenue, profitability, and cash flow are expected to continue to grow due to the company's strong product portfolio and ongoing investments in key growth areas. Additionally, the company's focus on reducing their debt and potential for mergers and acquisitions in the future make them an attractive investment opportunity.

Bears say

Bioventus is projected to face challenges in building the PNS business, however, management plans to make significant investments in growth drivers such as PNS, PRP, ultrasonics, and international growth. In the most recent quarter, the company saw an increase in revenue in the surgical solutions business, driven by growth in bone graft substitutes, but a decline in international revenue due to unfavorable order timing and difficult capital sales comparisons in ultrasonics. These factors may continue to negatively impact the company's overall financial performance.

Bioventus (BVS) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bioventus and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bioventus (BVS) Forecast

Analysts have given Bioventus (BVS) a Buy based on their latest research and market trends.

According to 3 analysts, Bioventus (BVS) has a Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bioventus (BVS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.